News

We’re talking about how younger women and men can monitor for breast cancer and recent updates in screening guidelines.

A man from Columbia, Missouri, got a new heart and a second chance at life, marking the 1,000th heart transplant at Saint Luke's Mid America Heart Institute.

Semaglutide improved symptoms, physical limitations, and exercise capacity in patients with obesity and heart failure across the spectrum of left ventricular ejection fraction.

Dr. Timothy Bateman spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.

This week during Breast Cancer Awareness Month, we’re talking about metastatic breast cancer and Saint Luke’s Koontz Center—the region’s only center dedicated and designed specifically for these patients.

Saint Luke’s program becomes the 23rd institution in the U.S. to perform 1,000 heart transplants.

TCTMD talked to Dr. Paul Chan and Dr. Anezi Uzendu about the new study's findings.

In the past, many women born with a heart condition were told they would not be able to birth children safely.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.